Form SC 13G/A INTERCEPT PHARMACEUTICAL Filed by: AMERIPRISE FINANCIAL INC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/9/2026
- Nasdaq ends sharply higher; chip surge offsets Iran worries
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil prices settle 2% lower as economic worries outweigh supply risks
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- GameStop stockholders approve share count increase to 2.5 billion
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- AI bubble fears mount as Zuckerberg admits agent delays and Burry shorts sector
- Key things to know ahead of SK Hynix’s blockbuster US listing
Intercept (ICPT) NASH Trial Amendment Doesn't Change Probability of Success - Cantor Fitzgerald
February 10, 2017 12:39 PM ESTCantor Fitzgerald analyst Elemer Piros doesn't have much nice to say about Intercept Pharmaceuticals (NASDAQ: ICPT) REGENERATE trial change. The firm maintained an Underweight rating and price target of $60.
The analyst does not see a change to their probability of success... More
Intercept Pharmaceuticals (ICPT) Trial Amendments 'Increase Probability for Success' - Wedbush
February 10, 2017 12:31 PM ESTWedbush analyst Liana Moussatos reiterated her Outperform rating and $224 price target on Intercept Pharmaceuticals (NASDAQ: ICPT) after protocol amendments to the Phase 3 REGENERATE trial, which she said er the bar for success, while retaining significant upside.
Moussatos commented, "Intercept announced two protocol amendments to... More
